14.656 -1.344 (-8.4%) | 03-28 13:41 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 517.24 | 1-year : | 604.13 |
Resists | First : | 442.84 | Second : | 517.24 |
Pivot price | 420.47 | |||
Supports | First : | 406.17 | Second : | 383.51 |
MAs | MA(5) : | 436.41 | MA(20) : | 417.67 |
MA(100) : | 362.28 | MA(250) : | 292.38 | |
MACD | MACD : | 11.7 | Signal : | 10 |
%K %D | K(14,3) : | 89.6 | D(3) : | 87.4 |
RSI | RSI(14): 66.5 | |||
52-week | High : | 442.84 | Low : | 184.5 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ BLD ] has closed below upper band by 15.9%. Bollinger Bands are 12.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 438.7 - 441.34 | 441.34 - 443.88 |
Low: | 426.03 - 429.17 | 429.17 - 432.17 |
Close: | 433.65 - 438.28 | 438.28 - 442.72 |
Thu, 28 Mar 2024
Boundless Bio's 'BOLD' IPO Reels In $100M for a New Kind of Cancer Drug - MedCity News
Thu, 28 Mar 2024
Boundless Bio raises $100m as IPO market rouses - Pharmaceutical Technology
Thu, 28 Mar 2024
Boundless Bio Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Thu, 28 Mar 2024
Boundless Bio Launches $100M IPO to Advance Cancer Therapy Candidates - BioSpace
Thu, 28 Mar 2024
Boundless Bio prices $100M IPO at $16 per share - MSN
Wed, 27 Mar 2024
Boundless Bio Announces Pricing of Initial Public Offering - The Bakersfield Californian
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
Exchange:
NASDAQ
|
|
Sector:
|
|
Industry:
|
|
Shares Out | 32 (M) |
Shares Float | 31 (M) |
Held by Insiders | 0.4 (%) |
Held by Institutions | 97.8 (%) |
Shares Short | 506 (K) |
Shares Short P.Month | 505 (K) |
EPS | 19.34 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 81.18 |
Profit Margin | 11.8 % |
Operating Margin | 16.4 % |
Return on Assets (ttm) | 11.4 % |
Return on Equity (ttm) | 27.3 % |
Qtrly Rev. Growth | 1.7 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 163.15 |
EBITDA (p.s.) | 32.37 |
Qtrly Earnings Growth | 1.8 % |
Operating Cash Flow | 849 (M) |
Levered Free Cash Flow | 679 (M) |
PE Ratio | 22.75 |
PEG Ratio | 2 |
Price to Book value | 5.42 |
Price to Sales | 2.69 |
Price to Cash Flow | 16.47 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |